Biology Reference
In-Depth Information
References
[1] Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside.
Blood 2009;114:4327-36.
[2] Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science
1990;248:1349-56.
[3] Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation:
challenges and new developments. Immunol Rev 2009;229:271-93.
[4] Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus host
disease: therapeutic implications. Bone Marrow Res 2011;2011:976793.
[5] Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with
clinical application. Immunity 2006;24:233-8.
[6] Shahinian A, Pfeffer K, Kelvin P, Kundig T, Kishihara K, Wakeham A, et al. Differential
T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-12.
[7] Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4
can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
[8] Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-
4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, reveal-
ing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
[9] Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science
1995;270:985-8.
[10] Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator.
Immunity 1997;7:445-50.
[11] Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, et al. Induction of
alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interac-
tion of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-73.
[12] Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1
interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the
major histocompatibility complex barrier in mice. Blood 1994;83:3815-25.
[13] Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, et al.
Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits
murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T
cells. J Immunol 1996;157:3250-9.
[14] Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/
B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed
post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid
or lymphoid leukemia cells. J Immunol 1997;159:3460-73.
[15] Ogawa S, Nagamatsu G, Watanabe M, Watanabe S, Hayashi T, Horita S, et al. Opposing
effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/induc-
ible costimulator antibody on the development of acute versus chronic graft-versus-
host disease. J Immunol 2001;167:5741-8.
[16] Ohata J, Sakurai J, Saito K, Tani K, Asano S, Azuma M. Differential graft-versus-leukae-
mia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease
prophylaxis. Clin Exp Immunol 2002;129:61-8.
[17] Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of
CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipi-
ents of MHC disparate T cells. J Immunol 1999;162:6368-77.
[18] Bosch-Vizcaya A, Perez-Garcia A, Brunet S, Solano C, Buno I, Guillem V, et al. Donor
CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hemato-
poietic stem cell transplantation from HLA-identical sibling donors. Biol Blood Marrow
Transplant 2012;18:100-5.
[19] Li J, Semple K, Suh WK, Liu C, Chen F, Blazar BR, et al. Roles of CD28, CTLA4, and
inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow
Transplant 2011;17:962-9.
[20] Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. CD28-specific antibody prevents graft-versus-
host disease in mice. J Immunol 2000;164:4564-8.
[21] Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, et al. Inducing CTLA-4-
dependent immune regulation by selective CD28 blockade promotes regulatory T cells
in organ transplantation. Sci Transl Med 2010;2; 17ra10.
[22] Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discovery
2011;10:655-6.
[23] Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, et al. Topological
requirements and signaling properties of T cell-activating, anti-CD28 antibody super-
agonists. [comment]. J Exp Med 2003;197:955-66.
215
Search WWH ::
Custom Search